Introduction
============

Hepatocellular carcinoma (HCC) is the fifth common cancer and the third leading cause of cancer-related death globally. It is a global health problem and a common liver malignancy in the world [@B1]-[@B3]. Several studies suggest that HCC shows great geographical variation, and more than 600,000 people die from HCC every year, and about \> 75% of these HCC cases occur in the Asia-Pacific region [@B4],[@B5]. China has a very high HCC incidence, with approximately 55% of annual new cases of HCC in the world [@B1],[@B6],[@B7]. Since the 1990s, HCC has been the second leading cause of cancer deaths in China [@B8]. Up to date, the exact mechanism of HCC remains poorly understood. There were several studies suggested that the human X-ray repair complementing group 1 gene (*XRCC1*) was an important candidate gene which influencing HCC risk [@B9]-[@B21]. Many single nucleotide polymorphisms (SNPs) in *XRCC1* gene, such as Arginine (Arg)194 Tryptophan (Trp), Arg280 Histidine (His) and Arg399 Glutanine (Gln), have been analyzed to evaluate the possible association between the genetic variants of *XRCC1* gene and the risk of HCC [@B9]-[@B16]. Fortunately, several studies have proved that the genetic variants of *XRCC1* gene were associated with HCC [@B9]-[@B16]. However, there were no similar studies on the association between c.1161G\>A and c.1779C\>G genetic variants and the risk of HCC. Therefore, the purpose of this study was to assess whether these two genetic variants influence the risk of HCC.

Materials and methods
=====================

Study population
----------------

A total of 623 HCC patients and 639 cancer-free controls were enrolled from Ruikang Hospital (Guangxi University of Chinese Medicine, Nanning, Guangxi Zhuang Autonomous Region, China) between January 2009 to December 2011 in this case-control study. All HCC patients and cancer-free controls were unrelated Han Chinese. HCC patients were diagnosed by doctors based on the standards established by Chinese Society of Liver Cancer (CSLC). Cancer-free controls were matched with HCC patients with regard to gender and age, excluding those with a history of HCC and other medical diseases. The clinical characteristics were collected in Table [1](#T1){ref-type="table"}, including gender, age, alcohol drinking, tobacco smoking, hypertension, diabetes mellitus, family history of HCC, hepatitis B virus ( HBV) serological markers, and serum alpha-fetoprotein (a-FP) levels. This study was approved by the ethics committee of Ruikang Hospital (Guangxi University of Chinese Medicine, Nanning, Guangxi Zhuang Autonomous Region, China). Informed consent was obtained from all the subjects enrolled in the study.

*XRCC1* variants genotyping
---------------------------

Genomic DNA was isolated from venous blood of all the subjects using the standard protocol [@B22]. PCR primers were designed using Primer Premier 5.0 software. Primers, region, fragment size, and annealing temperature were summarized in Table [2](#T2){ref-type="table"}. *XRCC1* genetic variants were genotyped by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and almost 10% of the samples showing genetic polymorphisms for *XRCC1* gene were verified by DNA sequencing (ABI3730xl DNA Analyzer, Applied Biosystems, Foster City, CA) to ensure the concordance of the PCR-RFLP results. The PCR reactions were performed in a total volume of 20 µL solution containing 50ng template DNA, 1×buffer (Tris-HCl 100 mmol/L, pH 8.3; KCl 500 mmol/L), 0.25 µmol/L primers, 2.0 mmol/L MgCl~2~, 0.25 mmol/L dNTPs (Bioteke Corporation, Beijing, China), and 0.5U Taq DNA polymerase (Promega, Madison, WI, USA). The PCR conditions were as follows: initial denaturation at 94°C for 5 min, followed by 35 cycles at 94°C for 30 s, at the corresponding temperature (given in Table [2](#T2){ref-type="table"}) for 30 s, at 72°C for 30 s, and a final extension at 72°C for 5 min. The PCR amplified products were digested with 5 units corresponding restriction enzyme (MBI Fermentas, St. Leon-Rot, Germany, Table [2](#T2){ref-type="table"}) at 37°C for 10 h following the supplier\'s manual and electrophoresed on 2.5% agarose gel containing ethidium-bromide.

Statistical analysis
--------------------

The chi-squared (χ^2^) test was performed to assess the Hardy-Weinberg equilibrium in genotype/allele frequencies, and compare the differences of the clinical characteristics between HCC patients and cancer-free controls. The odds ratios (ORs) with its 95% confidence intervals (95% CIs) of the association between allele/genotype frequencies and the risk of HCC were evaluated by multivariate logistic regression models. A P value \< 0.05 was suggested as statistically significant. The statistical analyses were analyzed using the Statistical Package for Social Sciences software (SPSS, Windows version release 15.0; SPSS Inc.; Chicago, IL, USA).

Results
=======

Subjects and general characteristics
------------------------------------

In total, 1262 subjects were recruited in this case-control study, including 623 HCC cases and 639 cancer-free controls. The clinical characteristics of subjects were performed in Table [1](#T1){ref-type="table"}. There was no statistically significant difference between HCC patients and cancer-free controls in terms of age and gender (P = 0.3851 and P = 0.4423, respectively). Furthermore, no statistically significant differences were obtained in other clinical characteristics, such as alcohol drinking, tobacco smoking, hypertension, and diabetes mellitus between HCC cases and cancer-free controls (P = 0.3115, P = 0.6512, P = 0.8074 and P = 0.1363, respectively).

Identification and genotyping of *XRCC1*variants
------------------------------------------------

Two allelic variants (c.1161G\>A and c.1779C\>G) were found by PCR-RFLP and DNA sequencing methods in this study. Based on the reference sequences GenBank ID: NC_000019.9, NM_006297.2 and NP_006288.2, the sequence analysis suggested that c.1161G\>A allelic variant was a synonymous mutation, which caused by G to A mutations in exon10 of *XRCC1* gene \[p. Leucine (Leu) 387Leu\]. As for the c.1779C\>G variant, sequence analysis proved that this variant was caused by C to G mutations in exon16 of *XRCC1* gene, which leading to the Serine (Ser) to Arginine amino acid (Arg) replacement (p.Ser593Arg). The PCR amplified products of c.1161G\>A variant was digested with *Mae*I restriction enzyme and divided into three genotypes, GG (213 bp), GA (213, 183 and 30 bp) and AA (183 and 30 bp, Table [2](#T2){ref-type="table"}). As for the c.1779C\>G variant, it was digested with *Alu*I restriction enzyme and divided into three genotypes, CC (177 and 58 bp), CG (235, 177 and 58 bp) and GG (235 bp, Table [2](#T2){ref-type="table"}). The genotype/allele frequencies of these two genetic variants in both HCC patients and cancer-free controls were performed in Table [3](#T3){ref-type="table"}. As shown in Table [3](#T3){ref-type="table"}, the genotype distributions of these two genetic variants in the subjects didn\'t significantly deviate from Hardy-Weinberg equilibrium (all P values \> 0.05). Allele-G and allele-C were predominant alleles in the studied group for c.1161G\>A and c.1779C\>G variants, respectively. As for the c.1161G\>A variant, the allele frequencies of HCC patients (G, 61.16%; A, 38.84%) were statistically significantly different from cancer-free controls (G, 70.03%; A, 29.97%; χ^2^= 22.0390, P \< 0.001). Genotype frequencies in HCC patients were not consistent with cancer-free controls, the differences being statistically significant (χ^2^= 22.4559, P \< 0.001). As for the c.1779C\>G variant, the allele frequencies of HCC patients (C, 61.08%; G, 38.92%) were statistically significantly different from cancer-free controls (C, 70.34%; G, 29.66%, χ^2^= 24.075, P \< 0.001). The genotype distributions in HCC patients were statistically significantly different from cancer-free controls (χ^2^= 23.4151, P \< 0.001, Table [3](#T3){ref-type="table"}).

*XRCC1* variants and the risk of HCC
------------------------------------

We found that the genotypes/alleles from the c.1161G\>A and c.1779C\>G variants were statistically associated with the risk of HCC (Table [4](#T4){ref-type="table"}). As for the c.1161G\>A variant, statistically significantly increased risk of HCC were detected in the homozygote comparison (AA versus (vs.) GG: OR = 2.36, 95% CI 1.63-3.40, χ^2^= 21.63, P \< 0.001), heterozygote comparison (GA vs. GG: OR = 1.34, 95% CI 1.06-1.70, χ^2^= 5.79, P = 0.016), dominant model (AA/GA vs. GG: OR = 1.51, 95% CI 1.21-1.89, χ^2^= 13.17, P \< 0.001), recessive model (AA vs. GA/GG: OR = 2.04, 95% CI 1.44-2.88, χ^2^= 16.66, P = \< 0.001) and allele contrast (A vs. G: OR = 1.48, 95% CI 1.26-1.75, χ^2^= 22.03, P \< 0.001, Table [4](#T4){ref-type="table"}). Similarly, as for the c.1779C\>G variant, we also found that there were statistically significant differences in the homozygote comparison (GG vs. CC: OR = 2.17, 95% CI 1.51-3.12, χ^2^= 18.07, P \< 0.001), heterozygote comparison (CG vs. CC: OR = 1.55, 95% CI 1.22-1.96, χ^2^= 12.98, P \< 0.001), dominant model (GG/GC vs. CC: OR = 1.67, 95% CI 1.33-2.09, χ^2^= 20.03, P \< 0.001), recessive model (GG vs. GC/CC: OR = 1.75, 95% CI 1.24-2.46, χ^2^= 10.44, P = 0.001) and allele contrast (G vs. C: OR = 1.51, 95% CI 1.28-1.78, χ^2^= 24.07, P \< 0.001, Table [4](#T4){ref-type="table"}).

Discussion
==========

Emerging evidence suggests that HCC is a common and polygenic malignant solid cancers resulting from complex interactions between environmental and genetic factors [@B23]-[@B27]. It represents a major and constantly rising health burden worldwide. Previous studies have approved that genetic factors have the key roles in the pathogenesis of HCC [@B28]-[@B32]. In recent years, the *XRCC1*gene is regarded as an important candidate gene for HCC, and several association studies have been conducted to assess the role of Arg194Trp, Arg280His and Arg399Gln variants on the risk of HCC [@B9]-[@B16]. The findings from the previous association studies still remain conflicting rather than conclusive [@B9]-[@B16]. Kiran et al., indicated that Arg194Trp, Arg280His and Arg399Gln variants were significantly associated with the risk of hepatitis virus related HCC in Indian population [@B12]. Pan et al., suggested that the Arg399Cln Arg/Gln indicated an increased risk of HCC, especially for patients above 50 years old or with drinking habits in Chinese population [@B13]. However, Liu et al., demonstrated that the Arg399Gln is not statistically associated with altered HCC susceptibility according to the findings from meta-analysis method [@B17]. However, up to date, the c.1161G\>A and c.1779C\>G genetic variants have not been analyzed in the risk of HCC. In this case-control study, we evaluated the association between these two SNPs and the risk of HCC in Chinese Han population. Results from this study, statistical significant differences were shown in allele and genotype frequencies between HCC patients and cancer-free controls for these two genetic variants (Table [3](#T3){ref-type="table"}). As for the c.1161G\>A variant, the risk of HCC was significantly higher for AA genotype compared to GG genotype and GA/GG carriers. As for the c.1779C\>G variant, the GG genotype was significantly associated with the increased risk of HCC compared to CC genotype and CG/CC carriers. The allele-A of c.1161G\>A and allele-G of c.1779C\>G variants could contribute to the risk of HCC (Table [4](#T4){ref-type="table"}), and these two alleles might be associated with a protection from HCC. These genetic variants might affect the function of *XRCC1* protein in base excision DNA repair pathway, which is significantly associated with the risk of HCC. The results from the current study might provide more evidences to assess the role of *XRCC1* gene in the development of HCC. Our date indicated that the c.1161G\>A and c.1779C\>G variants of *XRCC1* gene were statistically associated with the increased risk of HCC in Chinese Han population.

In conclusion, to the best of our knowledge, this is the first investigation about the association between *XRCC1* gene c.1161G\>A and c.1779C\>G genetic variants and HCC risk. Our findings supported that the *XRCC1* genetic variants may be used as molecular markers for assessing the risk of HCC. Further studies will be needed to confirm these findings and explain the molecular mechanisms between *XRCC1*genetic variants and HCC risk on larger different populations.
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###### 

The clinical characteristics of hepatocellular carcinoma (HCC) cases and controls.

  Characteristics                  Cases (n)     \%            Controls (n)   \%       χ^2^-value   P-value
  -------------------------------- ------------- ------------- -------------- -------- ------------ ---------
  **Number**                       623                         639                                  
  **Gender (n)**                                                              0.5902   0.4423       
  Male                             369           59.23         392            61.35                 
  Female                           254           40.77         247            38.65                 
  **Age (years)**                                                                                   
  Mean ± SD                        58.25±13.28   59.22±14.37   0.7544         0.3851                
  \< 55                            387           62.12         412            64.48                 
  ≥ 55                             236           37.88         227            35.52                 
  **Tobacco smoking**                                                         0.2043   0.6512       
  Yes                              348           55.86         365            57.12                 
  No                               275           44.14         274            42.88                 
  **Alcohol drinking**                                                        1.0243   0.3115       
  Yes                              351           56.34         378            59.15                 
  No                               272           43.66         261            40.85                 
  **Hypertension (n)**                                                        0.0594   0.8074       
  Yes                              105           16.85         111            17.37                 
  No                               518           83.15         528            82.63                 
  **Diabetes mellitus(n)**                                     2.2197         0.1363                
  Yes                              121           19.42         146            22.85                 
  No                               502           80.58         493            77.15                 
  **Family history of HCC (n)**                                                                     
  Yes                              42            6.74          \-                                   
  No                               581           93.26         \-                                   
  **HBV serological markers(n)**                                                                    
  HBs Ag (+)                       158           25.36         \-                                   
  HBs Ag (-)                       465           74.64         \-                                   
  **Serum a-FP levels**                                                                             
  \< 400 ng/ml                     210           33.71         \-                                   
  \> 400 ng/ml                     413           66.29         \-                                   

###### 

Primers and PCR-RFLP analysis for genotyping *XRCC1* gene polymorphisms.

  -------------------------------------------------------------------------------------------------------------------------------------------
  SNPs         Primer sequences                Annealing\         Amplification fragment (bp)   Region   Restriction enzyme   Genotype (bp)
                                               temperature (°C)                                                               
  ------------ ------------------------------- ------------------ ----------------------------- -------- -------------------- ---------------
  c.1161G\>A   5′-GAGGCCGCATCGTGCGTAAG-3′      66.4               213                           Exon10   *Mae*I               GG:213

               5′-TGCCCCGCTCCTCTCAGTAGTCT-3′                                                                                  GA:213,183,30

                                                                                                                              AA:183,30

  c.1779C\>G   5′-AGGACAATATGAGTGACCGGGT-3′    59.9               235                           Exon16   *Alu*I               CC:177,58

               5′-CATTGCAACTGTAGATCCATCG-3′                                                                                   CG:235,177,58

                                                                                                                              GG:235
  -------------------------------------------------------------------------------------------------------------------------------------------

Note: SNPs, single nucleotide polymorphisms; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.

###### 

The genotypic and allelic frequencies of*XRCC1* polymorphisms in case and groups.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Groups               c.1161G\>A       c.1779C\>G                                                                                                                                                    
  -------------------- ---------------- ---------------- ------------ ------------ ---------------- --------------- -------- ------------ ------------ ----------- ------------ ------------ -------- --------
  Cases (n = 623)      241(38.68)       280(44.94)       102(16.37)   762(61.16)   484(38.84)       1.8189          0.4027   235(37.72)   291(46.71)   97(15.57)   761(61.08)   485(38.92)   0.1932   0.9079

  Controls (n = 639)   31\              271\             56\          895\         383\             0.0687          0.9663   321\         257\         61\         899\         379\         0.8294   0.6605
                       (48.83)          (42.41)          (8.76)       (70.03)      (29.97)                                   (50.23)      (40.22)      (9.55)      (70.34)      (29.66)               

  Total (n = 1262)     553\             551\             158\         1657\        867\             1.2880          0.5252   556\         548\         158\        1660\        864\         1.6012   0.4491
                       (43.82)          (43.66)          (12.52)      (65.65)      (34.35)                                   (44.06)      (43.42)      (12.52)     (65.77)      (34.23)               

                       χ^2^= 22.4559,   χ^2^= 22.0390,                             χ^2^= 23.4151,   χ^2^= 24.075,                                                                                     

  P \< 0.001           P \< 0.001                                     P \< 0.001   P \< 0.001                                                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Association between hepatocellular carcinoma (HCC) risk and*XRCC1* gene polymorphisms.

  SNPs         Comparisons                           Test of association           
  ------------ ------------------------------------- --------------------- ------- ----------
  c.1161G\>A   Homozygote comparison                                               
               (AA vs. GG) Heterozygote comparison   2.36 (1.63-3.40)      21.63   \< 0.001
               (GA vs. GG) Dominant model            1.34 (1.06-1.70)      5.79    0.016
               (AA/GA vs. GG) Recessive model        1.51 (1.21-1.89)      13.17   \< 0.001
               (AA vs. GA/GG) Allele contrast        2.04 (1.44-2.88)      16.66   \< 0.001
               (A vs. G)                             1.48 (1.26-1.75)      22.03   \< 0.001
  c.1779C\>G   Homozygote comparison                                               
               (GG vs. CC) Heterozygote comparison   2.17 (1.51-3.12)      18.07   \< 0.001
               (CG vs. CC) Dominant model            1.55 (1.22-1.96)      12.98   \< 0.001
               (GG/CG vs. CC) Recessive model        1.67 (1.33-2.09)      20.03   \< 0.001
               (GG vs. CG/CC) Allele contrast        1.75 (1.24-2.46)      10.44   0.001
               (G vs. C)                             1.51 (1.28-1.78)      24.07   \< 0.001

SNPs, single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; vs., versus.
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